KMM Group Expands Leadership, Manufacturing Capacity and Workforce

The appointments follow
"We are excited to welcome Amy and Erica to KMM as we build on the strength of our team and invest in the capabilities needed for continued expansion," King said. "Amy's decades of operations and supply chain experience and Erica's perspective, shaped by leading finance through complex manufacturing transitions, align naturally with where KMM is headed."
Goff brings nearly 30 years of medical device and contract manufacturing experience. Most recently, she served as vice president at Canadian Hospital Specialties, where she led the transformation of North American supply chain teams. She previously spent nearly 20 years with Argon Medical, with responsibility spanning seven manufacturing facilities and five distribution centers across seven countries.
"I joined KMM because the company already has an extraordinary combination of technical capability, skilled people and pride in the work," Goff said. "My role is to listen to the people closest to that work and strengthen the processes that will allow the organization to expand."
Blake brings more than 25 years of financial leadership across medical device, life sciences and specialty manufacturing organizations. She most recently served as head of finance for
The leadership expansion coincides with KMM's broader capital investment and workforce growth plans to increase production capacity.
About KMM Group
KMM Group is a premier contract manufacturer specializing in complex, tight-tolerance components for the medical device industry and other highly demanding markets. KMM solves complex, failure-intolerant engineering challenges through integrated capabilities, technical expertise and scalable production. For more information, visit kmmgrp.com.
MEDIA CONTACT:
Amy Rodgers
Director of Marketing
[email protected]
(215) 280-1374



View original content to download multimedia:https://www.prnewswire.com/news-releases/kmm-group-expands-leadership-manufacturing-capacity-and-workforce-302896743.html
SOURCE KMM Group
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
- Crypto News Today: Swiss Retail Bitcoin ETF Approval Meets Remittix’s $0.28 Entry and November Launch Countdown
- Best AI Tools for Small Business Marketing (2026): CapCut Featured for Creating Professional Video and Visual Content by Expert Consumers
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share